Skip to content
Par Drugs & Chemical logo

Par Drugs & Chemical

Par Drugs & Chemicals Ltd

PAR NSE
₹107.90 No trade today
P/E
9.16
View as Markdown
MCP
Close 4 Nov 2026 ₹107.90 +8.72 +8.79% 1Y
Start ₹99.18

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
14.60%
Debt to Equity
0.00
EPS (TTM)
₹11.78
Book Value
₹96.98
Market Cap
—
P/E (TTM)
9.16
P/B
1.11
ROE
9.95%
Dividend Yield
1.10%
EBITDA
₹21.10 Cr
52W High
₹180.00
52W Low
₹78.05
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Par Drugs & Chemical peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Par Drugs & Chemical (this company)
₹107.909.16₹137 Cr1.111.10%9.95%14.60%₹109 Cr₹14 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.70%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

63 Good

Data confidence 98/100

surveillance:ESM1

Category scores

Quality
77
Strong
Returns, margins, earnings quality 22% weight
Valuation
83
Strong
Cheap vs sector & own history 24% weight
Growth
43
Weak
Sales & profit trajectory 9% weight
Financial Health
81
Strong
Solvency, leverage, coverage 9% weight
Momentum
74
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Stock is trading at 1.15 times its book value

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has a low return on equity of 13.4% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish973
OscillatorsNeutral171
Moving AveragesStrong Bearish802

Key readings

RSI (14)
42.99
Neutral
MACD (12,26,9)
−3.06
Bullish
SMA (50)
122.93
Bearish
SMA (200)
100.13
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+12.16%
5Y+11.26%
3Y+2.70%
1Y+2.97%
TTM+4.28%

Net profit

Net profit growth by window
10YZero base
5Y+1.61%
3Y+5.73%
1Y0.00%
TTM+2.33%

Operating cash flow

Operating cash flow growth by window
10Y+8.62%
5Y+5.92%
3Y+7.17%
1Y0.00%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−4.86 pp
5Y−9.88 pp
3Y−2.40 pp
1Y−3.45 pp
TTM+0.26 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹49.00 Cr
Mar 2018₹42.00 Cr
Mar 2019₹46.00 Cr
Mar 2020₹56.00 Cr
Mar 2021₹61.00 Cr
Mar 2022₹75.00 Cr
Mar 2023₹96.00 Cr
Mar 2024₹96.00 Cr
Mar 2025₹101 Cr
Mar 2026₹104 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2.00 Cr
Mar 2018₹2.00 Cr
Mar 2019₹3.00 Cr
Mar 2020₹5.00 Cr
Mar 2021₹12.00 Cr
Mar 2022₹9.00 Cr
Mar 2023₹11.00 Cr
Mar 2024₹14.00 Cr
Mar 2025₹13.00 Cr
Mar 2026₹13.00 Cr

Quarterly Results

₹ Cr
PAR quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
22.93
25.89
24
22.82
22.61
34.66
21.38
22.33
26.05
28.66
29.34
19.61
31.28
27.43
Expenses
18.79
18.53
18.77
16.72
18.37
23.25
19.95
19.9
22.49
22.6
23.29
18.17
24.91
22.93
Operating Profit
4.14
7.36
5.23
6.1
4.24
11.41
1.43
2.43
3.56
6.06
6.05
1.44
6.37
4.5
OPM %
18.05%
28.43%
21.79%
26.73%
18.75%
32.92%
6.69%
10.88%
13.67%
21.14%
20.62%
7.34%
20.36%
16.41%
Other Income
0.01
0.05
0.23
−0.05
0.07
1.02
0.27
0.79
1.84
0.48
1.33
0.36
0.94
0
Interest
0.02
0.03
0.02
0.05
0.02
0.03
0.01
0.02
0.02
0.05
0.01
0.04
0.02
0.02
Depreciation
0.83
0.85
0.87
0.89
0.9
0.91
0.91
0.92
0.9
0.94
0.93
0.93
0.96
0.94
PBT
3.3
6.54
4.57
5.11
3.39
11.49
0.77
2.28
4.48
5.55
6.44
0.83
6.33
3.54
Tax %
25.15%
25.27%
25.16%
27.2%
25.07%
25.15%
24.36%
27.63%
25.67%
25.59%
25.47%
−3.61%
25.59%
25.99%
Net Profit
2.47
4.89
3.42
3.72
2.53
8.6
0.58
1.65
3.33
4.13
4.8
0.85
4.71
2.63
EPS (₹)
2.01
3.97
2.78
3.02
2.06
6.99
0.47
1.34
2.71
3.36
3.9
0.69
3.83
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
PAR profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
33
33
49
42
46
56
61
75
96
96
101
104
109
Expenses
26
26
40
34
38
46
45
59
78
73
81
87
89
Operating Profit
7
7
8
8
8
9
16
16
18
23
20
17
20
OPM %
22%
22%
17%
19%
18%
17%
26%
22%
19%
24%
19%
17%
18%
Other Income
0
0
0
0
0
0
2
0
0
0
2
4
3
Interest
4
4
2
2
2
1
1
0
0
0
0
0
0
Depreciation
2
3
3
3
3
3
3
3
3
3
4
4
4
PBT
1
1
3
3
3
6
15
13
15
20
18
17
19
Tax %
27%
58%
42%
42%
24%
21%
21%
27%
25%
26%
26%
24%
—
Net Profit
1
0
2
2
3
5
12
9
11
14
13
13
14
EPS (₹)
1.65
0.78
3.43
2.78
2.79
3.87
9.44
7.49
9.21
11.78
10.86
10.65
11.78
Div. Payout %
0%
0%
0%
0%
0%
32%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
PAR balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
4
6
6
12
12
12
12
12
Reserves
9
9
11
12
25
34
46
48
59
73
87
100
Borrowings
38
36
31
29
12
6
8
0
0
0
0
0
Other Liabilities
9
10
12
10
11
13
16
19
18
16
20
17
Total Liabilities
59
58
56
54
51
60
76
79
89
102
119
129
Fixed Assets
45
43
42
39
36
34
30
34
38
41
39
36
CWIP
0
0
0
0
0
1
5
0
0
0
0
1
Investments
0
0
0
0
0
0
0
0
0
0
25
27
Other Assets
13
15
14
15
15
25
42
44
50
60
55
65
Total Assets
59
58
56
54
51
60
76
79
89
102
119
129

Cash Flow

₹ Cr
PAR cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
9
7
9
4
2
8
12
8
13
20
16
16
Investing
0
0
−2
−1
0
−1
0
−3
−7
−6
−25
−2
Financing
−9
−5
−8
−4
−2
1
2
−10
0
0
0
0
Net Cash Flow
−1
1
−1
0
0
7
14
−5
6
14
−9
14
Free Cash Flow
9
6
7
4
2
6
12
4
6
14
15
14
CFO/EBITDA
127
91
116
59
34
90
98
66
97
108
106
125

Ratios

PAR financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
81
61
75
67
81
75
90
65
52
60
42
Inventory Days
111
158
69
83
81
45
50
60
49
45
58
45
Days Payable
184
183
135
107
94
96
112
135
73
58
104
69
Cash Conversion Cycle
10
57
−5
51
55
30
13
14
40
40
15
19
Working Capital Days
61
66
−46
−26
13
39
24
61
50
40
39
31
ROCE %
10%
9%
12%
11%
12%
16%
25%
22%
23%
25%
18%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Par Drugs & Chemical insights

64 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 73.41%
  • Public 19.64%
  • Others 6.87%
  • DIIs 0.09%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

  • Concall · Jun 2023
    PPT
  • Concall · Jun 2023
    PPT
  • Concall · Mar 2023
    PPT
  • Concall · Mar 2023
    PPT
  • Concall · Feb 2023
    PPT

Frequently Asked Questions about Par Drugs & Chemical

What does Par Drugs & Chemicals Ltd do?
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals
Where is Par Drugs & Chemicals Ltd (PAR) listed?
Par Drugs & Chemicals Ltd trades as PAR on the NSE.
Which sector does Par Drugs & Chemicals Ltd belong to?
Par Drugs & Chemicals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd trades at a PE ratio of 9.16 as of 4 Nov 2026, on earnings per share of ₹11.78, against a book value of ₹96.98 per share.
What is the 52-week high and low of Par Drugs & Chemicals Ltd?
Over the last 52 weeks Par Drugs & Chemicals Ltd has traded between ₹78.05 and ₹180 as of 4 Nov 2026.
Does Par Drugs & Chemicals Ltd pay dividends?
Par Drugs & Chemicals Ltd has a dividend yield of 1.10%.
What is the Return on Equity (ROE) of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd reported a return on equity of 9.95%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals

Website pardrugs.com
Listed 16 Sep 2021
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PAR.md for Par Drugs & Chemicals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month